Global Hemochromatosis Pipeline Market Report 2021 Featuring Protagonist Therapeutics, Disc Medicine, Silence Therapeutics, & La Jolla Pharmaceutical Co –

Global Hemochromatosis Pipeline Market Report 2021 Featuring Protagonist Therapeutics, Disc Medicine, Silence Therapeutics, & La Jolla Pharmaceutical Co –

Global Hemochromatosis Pipeline Market Report 2021 Featuring Protagonist Therapeutics, Disc Medicine, Silence Therapeutics, & La Jolla Pharmaceutical Co –

DUBLIN–(BUSINESS WIRE)–The “Hemochromatosis – Pipeline Insight, 2021” drug pipelines has been added to’s offering.

This “Hemochromatosis – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hemochromatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hemochromatosis R&D. The therapies under development are focused on novel approaches to treat/improve Hemochromatosis.

Hemochromatosis Emerging Drugs Chapters

This segment of the Hemochromatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hemochromatosis Emerging Drugs

PTG-300: Protagonist Therapeutics

PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin that regulates iron homeostasis and controls the absorption, storage, and distribution of iron in the body and is based on peptide technology platform. PTG-300 (Rusfertide) is currently being evaluated for various disorders associated with iron overload and/or excessive erythrocytosis (red blood cell production). Rusfertide is being evaluated in a small open-label Phase 2 study in hereditary hemochromatosis (HH).

DISC-A: Disc Medicine

DISC-A is an oral small molecule and potent inhibitor of matriptase-2. It increases hepcidin levels and have potential therapeutic utility in diseases such as beta thalassemia, myelodysplastic syndrome and hemochromatosis. Disc Medicine is conducting preclinical studies of a matriptase-2 inhibitor as a potential treatment for rare hematologic disease.

Hemochromatosis: Therapeutic Assessment

This segment of the report provides insights about the different Hemochromatosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hemochromatosis

There are approx. 5+ key companies which are developing the therapies for Hemochromatosis. The companies which have their Hemochromatosis drug candidates in the most advanced stage, i.e. Phase III include, Sound Pharmaceuticals.


  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Hemochromatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hemochromatosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hemochromatosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hemochromatosis drugs.

Hemochromatosis Report Insights

  • Hemochromatosis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hemochromatosis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hemochromatosis drugs?
  • How many Hemochromatosis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hemochromatosis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hemochromatosis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hemochromatosis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Protagonist Therapeutics
  • Disc Medicine
  • Silence Therapeutics
  • La Jolla Pharmaceutical Company

Key Products

  • PTG-300
  • DISC-A
  • SLN-124
  • LJPC-401

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900